Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOTOX in pediatric upper limb spasticity
NCT01603615Phase 3Completed
- Sponsor
- Allergan
- Start
- Oct 2012
- Primary completion
- Sep 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of onabotulinumtoxinA in Upper limb spasticity, sponsored by Allergan. Primary endpoint: Percentage of Participants With at Least One Treatment-Emergent Adverse Event up to 60 weeks. Started Oct 2012; status: completed.
02
Drugs
onabotulinumtoxinA
03
Conditions
Upper limb spasticity
Beyond the preview
Go deeper on NCT01603615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01603615.